Compare FCEL & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCEL | XNCR |
|---|---|---|
| Founded | 1969 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2005 | 2013 |
| Metric | FCEL | XNCR |
|---|---|---|
| Price | $22.08 | $23.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $8.31 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 8.3M | 1.1M |
| Earning Date | 06-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.24 | ★ 65.36 |
| EPS | N/A | ★ N/A |
| Revenue | $89,437,000.00 | ★ $125,576,000.00 |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $42.46 | $4.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $3.78 | $7.13 |
| 52 Week High | $37.88 | $23.45 |
| Indicator | FCEL | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 73.35 |
| Support Level | $17.33 | $11.05 |
| Resistance Level | $26.16 | N/A |
| Average True Range (ATR) | 2.54 | 1.24 |
| MACD | 0.12 | 0.14 |
| Stochastic Oscillator | 47.61 | 95.91 |
FuelCell Energy Inc is a clean energy technology company engaged in the development, design, production, and servicing of high temperature fuel cells for clean electric power generation. The Company provides proprietary molten carbonate fuel cell systems that generate electricity electrochemically with ultra low emissions and high efficiency, and operates as a solutions provider managing the design, manufacturing, installation, and maintenance of its systems under long term power purchase, service, and engineering procurement agreements. The Company serves utilities, data centers, and commercial and industrial customers, and operates in the United States, South Korea, Europe, and Canada, with maximum revenue generated from the United States.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.